Scholarworks Repository

Rituximab for prevention and treatment of graft-versus-host disease.

Show simple item record

dc.contributor.author Kharfan-Dabaja M.A.
dc.contributor.author Cutler C.S.
dc.contributor.editor
dc.date May-2011
dc.date.accessioned 2017-10-05T15:39:43Z
dc.date.available 2017-10-05T15:39:43Z
dc.date.issued 2011
dc.identifier 10.1007/s12185-011-0855-2
dc.identifier.isbn
dc.identifier.issn 18653774
dc.identifier.uri http://hdl.handle.net/10938/17052
dc.description.abstract Growing understanding of the important role of B lymphocytes in alloreactivity has paved the way for evaluating anti-B cell therapy with rituximab in patients undergoing allogeneic hematopoietic cell transplantation. Data suggesting a beneficial reduction in incidence and severity of acute graft-versus-host disease (GVHD) are limited to non-randomized studies from single institutions using higher than conventional doses of rituximab. Additionally, rituximab is used as an effective treatment of corticosteroid-refractory chronic GVHD with good responses, particularly in cases of dermatologic and mucosal involvement. Post-transplant administration of rituximab appears to reduce the rate of chronic GVHD in preliminary studies.
dc.format.extent
dc.format.extent Pages: (578-585)
dc.language English
dc.publisher TOKYO
dc.relation.ispartof Publication Name: International journal of hematology; Publication Year: 2011; Volume: 93; no. 5; Pages: (578-585);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Rituximab for prevention and treatment of graft-versus-host disease.
dc.type Review
dc.contributor.affiliation Kharfan-Dabaja, M.A., Division of Hematology-Oncology and Bone Marrow Transplantation, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
dc.contributor.affiliation Cutler, C.S.
dc.contributor.authorAddress Kharfan-Dabaja, M.A.
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.authorEmail corey_cutler@dfci.harvard.edu
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Kharfan-Dabaja, MA
dc.contributor.authorInitials Cutler, CS
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Cutler, CS (reprint author), Harvard Univ, Sch Med, Div Hematol Malignancies, Dept Med Oncol,Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited ARAI S, 2008, ASH ANN M, V112, P466; Canninga-van Dijk MR, 2004, BLOOD, V104, P2603, DOI 10.1182-blood-2004-05-1855; CUTLER C, 2010, ASH ANN M, V116, P214; Cutler C, 2006, BLOOD, V108, P756, DOI 10.1182-blood-2006-01-0233; Do RKG, 2002, CYTOKINE GROWTH F R, V13, P19, DOI 10.1016-S1359-6101(01)00025-9; Eapen M, 2007, BIOL BLOOD MARROW TR, V13, P1461, DOI 10.1016-j.bbmt.2007.08.006; Glass B, 2008, ASH ANN M, V112, P1974; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038-82717; Kapur R, 2008, HAEMATOL-HEMATOL J, V93, P1702, DOI 10.3324-haematol.13311; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016-S1074-7613(02)00425-9; KHARFANDABAJA MA, 2010, BIOL BLOOD MARROW TR, V16, pS281, DOI 10.1016-j.bbmt.2009.12.376; Kharfan-Dabaja MA, 2009, BIOL BLOOD MARROW TR, V15, P1005, DOI 10.1016-j.bbmt.2009.04.003; Kharfan-Dabaja MA, 2008, BIOL BLOOD MARROW TR, V14, P121, DOI 10.1016-j.bbmt.2007.12.340; Khouri IF, 2008, BLOOD, V111, P5530, DOI 10.1182-blood-2008-01-136242; Khouri IF, 2007, BRIT J HAEMATOL, V137, P355, DOI 10.1111-j.1365-2141.2007.06591.x; Khouri IF, 2001, BLOOD, V98, P3595, DOI 10.1182-blood.V98.13.3595; Kim SJ, 2010, HAEMATOL-HEMATOL J, V95, P1935, DOI 10.3324-haematol.2010.026104; McIver Z, 2010, BIOL BLOOD MARROW TR, V16, P1549, DOI 10.1016-j.bbmt.2010.05.004; Mellon-Reppen S, 2010, BONE MARROW TRANSPL, V45, P1758, DOI 10.1038-bmt.2010.58; Mohty M, 2008, BONE MARROW TRANSPL, V41, P909, DOI 10.1038-bmt.2008.12; Okamoto M, 2006, LEUKEMIA, V20, P172, DOI 10.1038-sj.leu.2403996; Pidala J, 2011, INT J HEMATOL, V93, P206, DOI 10.1007-s12185-010-0747-x; Ratanatharathorn V, 2003, BIOL BLOOD MARROW TR, V9, P505, DOI 10.1016-S1083-8791(03)00216-7; Ratanatharathorn V, 2000, ANN INTERN MED, V133, P275; Ratanatharathorn V, 2009, BRIT J HAEMATOL, V145, P816, DOI 10.1111-j.1365-2141.2009.07674.x; RATANATHARATHOR.V, 2007, BLOOD, V110; Sarantopoulos S, 2009, BLOOD, V113, P3865, DOI 10.1182-blood-2008-09-177840; Sarantopoulos S, 2011, BLOOD, V117, P2275, DOI 10.1182-blood-2010-10-307819; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084-jem.192.11.1553; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172-JCI119822; Shimabukuro-Vornhagen A, 2009, BLOOD, V114, P4919, DOI 10.1182-blood-2008-10-161638; Teshima T, 2009, INT J HEMATOL, V90, P253, DOI 10.1007-s12185-009-0370-x; van Dorp S, 2009, BIOL BLOOD MARROW TR, V15, P671, DOI 10.1016-j.bbmt.2009.02.005; von Bonin M, 2008, TRANSPLANTATION, V86, P875, DOI 10.1097-TP.0b013e318183f662; Zaja F, 2007, BONE MARROW TRANSPL, V40, P273, DOI 10.1038-sj.bmt.1705725
dc.description.citedCount 11
dc.description.citedTotWOSCount 14
dc.description.citedWOSCount 13
dc.format.extentCount 8
dc.identifier.articleNo
dc.identifier.coden
dc.identifier.pubmedID 21547615
dc.identifier.scopusID 80052938004
dc.identifier.url
dc.publisher.address 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Int. J. Hematol.
dc.relation.ispartOfIssue 5
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle International journal of hematology
dc.relation.ispartofPubTitleAbbr Int. J. Hematol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 93
dc.source.ID WOS:000290732800003
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS melphalan, 148-82-3
dc.subject.otherChemCAS procarbazine, 366-70-1, 671-16-9
dc.subject.otherChemCAS rituximab, 174722-31-7
dc.subject.otherChemCAS vinblastine, 865-21-4
dc.subject.otherChemCAS Adrenal Cortex Hormones
dc.subject.otherChemCAS Antibodies, Monoclonal, Murine-Derived
dc.subject.otherChemCAS Melphalan, 148-82-3
dc.subject.otherChemCAS Procarbazine, 671-16-9
dc.subject.otherChemCAS Vinblastine, 865-21-4
dc.subject.otherChemCAS rituximab
dc.subject.otherIndex antineoplastic agent
dc.subject.otherIndex corticosteroid
dc.subject.otherIndex melphalan
dc.subject.otherIndex monoclonal antibody
dc.subject.otherIndex procarbazine
dc.subject.otherIndex rituximab
dc.subject.otherIndex vinblastine
dc.subject.otherIndex adult
dc.subject.otherIndex allotransplantation
dc.subject.otherIndex B cell lymphoma
dc.subject.otherIndex B lymphocyte
dc.subject.otherIndex clinical trial (topic)
dc.subject.otherIndex drug administration
dc.subject.otherIndex drug administration route
dc.subject.otherIndex drug effect
dc.subject.otherIndex graft versus host reaction
dc.subject.otherIndex hematopoietic stem cell transplantation
dc.subject.otherIndex human
dc.subject.otherIndex immunology
dc.subject.otherIndex immunosuppressive treatment
dc.subject.otherIndex methodology
dc.subject.otherIndex middle aged
dc.subject.otherIndex pathology
dc.subject.otherIndex pathophysiology
dc.subject.otherIndex review
dc.subject.otherIndex Adrenal Cortex Hormones
dc.subject.otherIndex Adult
dc.subject.otherIndex Antibodies, Monoclonal, Murine-Derived
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex B-Lymphocytes
dc.subject.otherIndex Clinical Trials as Topic
dc.subject.otherIndex Drug Administration Routes
dc.subject.otherIndex Drug Administration Schedule
dc.subject.otherIndex Graft vs Host Disease
dc.subject.otherIndex Hematopoietic Stem Cell Transplantation
dc.subject.otherIndex Humans
dc.subject.otherIndex Lymphoma, B-Cell
dc.subject.otherIndex Melphalan
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Procarbazine
dc.subject.otherIndex Transplantation Conditioning
dc.subject.otherIndex Transplantation, Homologous
dc.subject.otherIndex Vinblastine
dc.subject.otherKeywordPlus MONOCLONAL-ANTIBODY TREATMENT
dc.subject.otherKeywordPlus STEM-CELL TRANSPLANTATION
dc.subject.otherKeywordPlus REFRACTORY CHRONIC GVHD
dc.subject.otherKeywordPlus T-CELLS
dc.subject.otherKeywordPlus HEMATOPOIETIC TRANSPLANTATION
dc.subject.otherKeywordPlus ADOPTIVE IMMUNOTHERAPY
dc.subject.otherKeywordPlus B-CELLS
dc.subject.otherKeywordPlus LYMPHOMA
dc.subject.otherKeywordPlus SURVIVAL
dc.subject.otherKeywordPlus EXPRESSION
dc.subject.otherWOS Hematology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Scholarworks


Browse

My Account